Medicare Opens the Door to GLP-1 Weight-Loss Medications
The Medicare GLP-1 Bridge launches July 1, giving eligible seniors access to Wegovy and Zepbound for obesity treatment at $50 monthly.
Studies Suggest GLP-1 Medications May Help Slow Progression of Some Cancers
New research suggests GLP-1 medications may help slow the progression of certain cancers and reduce mortality risk, though more studies are needed.
GLP-1 Coverage Cuts by Medicaid
Some states are reconsidering Medicaid coverage for GLP-1 weight loss drugs amid rising costs. What does it mean for obesity treatment access?
Genetics May Shape the Future of GLP-1 Medications
Explore how genetics may influence the effectiveness of GLP-1 medications in children with obesity, and what personalized treatment means for the future.
The Rise of GLP-1 Medications in Pediatric Obesity: Breakthrough or Barrier?
Learn how GLP-1 medications are transforming childhood obesity treatment, including benefits, risks, and access challenges for families.
Family Values and Trust Shape Decisions About GLP-1 Meds for Kids
Caregivers’ trust, values, and food insecurity shape decisions about GLP-1 medications for children with obesity, highlighting need for shared decision-making.
GLP-1 Medications Should Be Paired With Lifestyle Modifications
Learn why lifestyle changes and tools like BrainWeighve are essential for lasting weight-loss success.
GLP-1 Medications Get a Major Price Drop As New Research Highlights Benefits for Youth
GLP-1 drug prices drop 30% as new research shows benefits for youth with type 2 diabetes amid rising childhood hypertension rates.
The Fast-Changing GLP-1 Landscape and Employee Coverage
GLP-1 drugs are reshaping diabetes and weight-loss care. Here’s how new treatments, pricing shifts, and coverage decisions impact employer health plans.
GLP-1 Drugs and Youth: Why More Research Is Needed Before Expanding Use
When it comes to kids and GLP-1s, careful consideration is just as vital as clinical innovation.